51 African Envoys and Senior Diplomats Visit CNBG Beijing Institute
Since the beginning of this year, the COVID-19 outbreak has brought grave challenges to the world. In the spirit of solidarity and cooperation, China and Africa helped each other to wade through this difficult time. In October, China and African countries welcomed an important moment—the 20th anniversary of the Forum on China-Africa Cooperation. Over the past 20 years, the forum has helped strengthen China-Africa relations and make the idea of building a China-Africa community of shared future deeply rooted in the minds of Chinese and African people. To further push forward China-Africa cooperation and strengthen exchange in science and technology, the African Department of China’s Ministry of Foreign Affairs invited 51 envoys and senior diplomats of African countries to visit Beijing Institute of Biological Products Co., Ltd. under CNBG affiliated to Sinopharm. There, they learned about China’s coronavirus vaccine research, clinical trials and production, and held talks with the company’s executives and researchers.
The African diplomatic corps visited the company’s vaccine manufacturing workshop, production control room and CNBG Museum, and then joined a seminar with the company’s staff.
In his speech at the seminar, Liu Jingzhen, chairman of Sinopharm, said that President Xi Jinping chaired the Extraordinary China-Africa Summit on Solidarity against COVID-19 in June and made a keynote speech at the event. In his speech, Xi stated that China is aggressively pursuing the development of a COVID-19 vaccine, and that African countries will be the first to benefit from the Chinese vaccine. Sinopharm will actively follow the instruction made by President Xi in this speech, Liu stressed. Though miles apart, Chinese and
African people care for each other from the bottom of their hearts. Sinopharm is willing to continue deepening cooperation against COVID-19 with African people and consolidating China-Africa friendship, so as to make contributions to building a China-Africa community of common health.
In his address, Wu Peng, director general of the African Department of the Ministry of Foreign Affairs, said Sinopharm is a pioneer in China-Africa healthcare cooperation, with outcomes benefiting every corner of the African continent. After the outbreak of the pandemic, it immediately offered a helping hand to Africa by providing medical supplies. China and Africa stand together through thick and thin after the COVID-19 outbreak. The Chinese side will continue upholding the idea of “one world, one family” and take on due responsibility for the global healthcare sector. China is willing to deepen cooperation with African countries to fight the pandemic and build the China-Africa community of common health. Vaccines are the most effective weapons to combat the virus. Following international norms, China is striving to push forward the research of vaccines. China has joined the COVAX program, and is willing to strengthen vaccine cooperation with Africa on the basis of fully respecting the willingness of the African side.
Inoussa Moustapha, Ambassador of Niger to China, remarked that while striving to push forward domestic epidemic control, China has never just mind its own business, but taken an active part in and made remarkable contribution to global anti-pandemic cooperation. A saying goes that “happiness is real only when it is shared.” China has joined COVAX, an important step taken by the country to build a community of common health for mankind. It has promised that a China-developed vaccine will serve as a global public good, and
developing countries will be the first to benefit from the Chinese vaccine. Moustapha also expressed his congratulations to Sinopharm on its commitment to the important task to develop coronavirus vaccines, as well as his hope for keyprogress in vaccine research, which is aspired by the whole world.
Zhang Yuntao, vice president of CNBG, introduced to the guests a series of major research results made by CNBG in the process of combating COVID-19, and the latest progress it made in the development of coronavirus vaccines. The seminar was presided over by Shi Shengyi, deputy CEO of Sinopharm. Fu Qiang, international chief engineer of Sinopharm, Wu Yonglin, president of CNBG, Wang Hui, director of Beijing Institute of Biological Products Co., Ltd., Liu Hongbing, director of the Office of Sinopharm Board of Directors, Jin Bin, director of the General Office of Sinopharm, and Ma Ke, deputy director of the Department of International Cooperation of Sinopharm, attended the seminar.